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Abstract
Introduction: Hypocalcaemia is a common postoperative complication, both after the resection of parathyroid adenoma associated with 
primary hyperparathyroidism and after total thyroidectomy due to thyroid cancer or nodular goitre. For a few years, in patients with 
postoperative hypoparathyroidism and severe hypocalcaemia, who cannot discontinue intravenous calcium preparations even with the 
use of high vitamin D doses, attempts have been made to add recombinant human parathormone (rhPTH) to the treatment schedule. In 
this work, for the first time in Poland, we demonstrate the potential use of teriparatide for the treatment of severe hypocalcaemia based 
on three different cases of postoperative hypoparathyroidism. 
Material and methods: Case 1. Female (52) with postoperative hypoparathyroidism, after total thyroidectomy and the removal of lower 
left parathyroid gland due to hyperparathyroidism, several weeks after the surgery still required intravenous calcium infusions because 
of tetany symptoms. Just one month of teriparatide treatment at 20 µg/0.08 mL given in daily subcutaneous injections proved sufficient 
to control calcium levels with oral calcium and vitamin D preparations during the next few days until total resolution of hypocalcaemia 
symptoms and the achievement and maintenance of laboratory normocalcaemia in the following weeks. 
Case 2. Female (33) with hypoparathyroidism following total thyroidectomy in 1996 because of papillary thyroid cancer, with congenital 
tubulopathy associated with renal loss of calcium and magnesium, and the symptoms of tetany recurring since the day of surgery, requir-
ing intravenous calcium administration every 2–3 days. Currently, the patient has been hospitalised because of venous port infection, 
the only venous access, which made intravenous therapy impossible. Because of the life-threatening condition of the patient, bridging 
teriparatide treatment was prepared (20 µg/0.08 mL). Complete resolution of clinical symptoms of hypocalcaemia was obtained with 
teriparatide doses given every 8–12 hours, which made dose reduction possible. 
Case 3. Female (52) after major oncological surgery because of laryngopharyngeal and cervical oesophageal cancer with the removal of 
parathyroid glands, fed through PEG, was admitted to hospital with the symptoms of tetany. Despite treatment intensification, the patient 
experienced a hypocalcaemic crisis during hospitalisation. Teriparatide treatment at 2 × 20 µg/day resulted in the resolution of tetany 
symptoms, with gradual normalisation of calcium-phosphate balance parameters during the following days. 
Conclusions: Based on the analysis of these cases, the conclusion was drawn that the use of recombinant human teriparatide allows 
for the control of severe hypocalcaemia requiring intravenous infusions of calcium in patients with postoperative hypoparathyroidism. 
(Endokrynol Pol 2016; 67 (4): 403–412)
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Streszczenie
Wstęp: Hipokalcemia jest częstym pooperacyjnym powikłaniem, zarówno po usunięciu gruczolaka przytarczyc w przebiegu pierwotnej 
nadczynności przytarczyc, jak i po całkowitej tyreoidektomii z powodu raka tarczycy lub wola guzowatego. Od kilku lat, u pacjentów 
z pooperacyjną niedoczynnością przytarczyc i ciężką hipokalcemią, u których nie można odstawić dożylnej terapii preparatami wapnia, 
nawet przy stosowaniu dużych dawek witaminy D, podejmowane są próby włączenia do leczenia ludzkiego rekombinowanego para-
thormonu (rhPTH). W niniejszej pracy, po raz pierwszy w Polsce, autorzy pracy wskazują na możliwość zastosowania teryparatydu 
w leczeniu ciężkiej hipokalcemii na podstawie trzech różnych przypadków pooperacyjnej niedoczynności przytarczyc. 
Materiał i metody: Przypadek 1: 52-letnia kobieta, z pooperacyjną niedoczynnością przytarczyc, po całkowitej tyreoidektomii i usunięciu 
przytarczycy dolnej lewej z powodu nadczynności przytarczyc, kilkanaście tygodni po operacji, z powodu objawów tężyczki, wciąż 
wymagająca stosowania dożylnych wlewów wapnia. Zastosowano jedynie miesięczną kurację teryparatydem w dawce 20 µg/0,08 ml 
w codziennych iniekcjach podskórnych, która okazała się wystarczająca do kontrolowania stężenia wapnia doustnymi preparatami 
wapnia i witaminy D, w ciągu następnych dni do całkowitego ustąpienia objawów hipokalcemii, a w kolejnych tygodniach uzyskania 
i utrzymania laboratoryjnych parametrów normokalcemii. 
Prof. Anhelli Syrenicz M.D., Ph.D., Department of Endocrinology, Metabolic Diseases, and Internal Diseases, Pomeranian Medical  
University, ul. Unii Lubelskiej 1, 71–252 Szczecin, Poland, phone: +48 91 425 35 40, fax: +48 91 425 35 42, e-mail: klinendo@pum.edu.pl
404
PR
A
C
E 
O
RY
G
IN
A
LN
E
Severe life-threatening hypocalcaemia and teriparatide  Elżbieta Andrysiak-Mamos et al.
Przypadek 2: 33-letnia kobieta, z niedoczynnością przytarczyc po całkowitej tyreoidektomii w 1996 roku z powodu raka brodawkowatego 
tarczycy, z wrodzoną tubulopatią przebiegającą z nerkową utratą wapnia i magnezu, od dnia operacji z nawracającymi objawami tężyczki 
wymuszającymi dożylne podawanie wapnia co 2–3 dni. Aktualnie hospitalizowana z powodu zakażenia portu naczyniowego, jedynego 
dostępu dożylnego, co uniemożliwiało dożylną terapię. Z uwagi na stan zagrożenia życia pacjentki, przygotowano leczenie pomostowe 
teryparatydem (20 µg/0,08 ml). Uzyskano całkowite ustąpienie klinicznych objawów hipokalcemii przy podawaniu dawki teryparatydu 
co 8–12 godzin, co pozwoliło na redukcję dawki leku. 
Przypadek 3: 52-letnia kobieta po rozległej operacji onkologicznej z powodu raka gardła dolnego i szyjnej części przełyku z usunięciem 
przytarczyc, odżywiana za pomocą PEG, przyjęta na oddział z objawami tężyczki. Mimo intensyfikacji leczenia, podczas hospitalizacji 
wystąpił u chorej przełom hipokalcemiczny. Zastosowany teryparatyd w dawce 2 × 20 µg/dobę spowodował ustąpienie objawów tężyczki, 
ze stopniową normalizacją parametrów gospodarki wapniowo-fosforanowej w następnych dniach. 
Wnioski: Na podstawie analizy przedstawionych przypadków wyciągnięto wniosek, że zastosowanie ludzkiego rekombinowanego 
teryparatydu pozwala na opanowanie ciężkiej hipokalcemii wymagającej dożylnych wlewów wapnia u pacjentów z pooperacyjną nie-
doczynnością przytarczyc. (Endokrynol Pol 2016; 67 (4): 403–412)
Słowa kluczowe: pooperacyjna niedoczynność przytarczyc; hipokalcemia; teryparatyd
Introduction
Hypocalcaemia is a frequent postoperative complication, 
following both the resection of parathyroid adenoma 
associated with primary hyperparathyroidism, and total 
thyroidectomy due to thyroid cancer, Graves’ disease, 
or nodular goitre [1–3]. In most cases, hypocalcaemia is 
of a temporary nature, although it does require calcium 
supplementation: initially by intravenous route, followed 
by oral administration with concomitant vitamin D sup-
ply [1, 3, 4]. The incidence of permanent postoperative 
hypoparathyroidism reported by reference surgical 
sites does not exceed 1–2% among operated patients. 
This group includes cases of severe hypocalcaemia, 
a life-threatening condition that cannot be managed by 
standard treatment with active vitamin D3 and calcium 
preparations. It requires intravenous infusion of calcium 
chloride repeated several times during a 24-hour period 
[5, 6]. Particularly severe hypocalcaemia may be observed 
in patients with postoperative hypoparathyroidism and 
an underlying condition making calcium deficiency even 
worse. These underlying conditions include, in particu-
lar: impaired calcium absorption from gastrointestinal 
tract or excessive calcium loss with urine associated with 
kidney disease [7, 8].
Scant literature, mainly based on case studies, indi-
cate that recombinant human parathormone (rhPTH) 
may be added to treatment in patients with severe 
hypocalcaemia in whom intravenous calcium therapy 
cannot be discontinued, even when high doses of 
alphacalcidol or calcitriol are used [4, 9, 10]. During 
the last few years, there were reports on teriparatide 
treatment of severe hypocalcaemia following surgery 
for both primary hyperparathyroidism and secondary 
hyperparathyroidism in renal post-transplant patients 
and in the treatment of chronic hypoparathyroidism, 
including in children [8, 11–14].
In Europe, recombinant human parathormone 
products are approved only for the treatment of post-
menopausal osteoporosis, idiopathic osteoporosis, os-
teoporosis associated with hypogonadism in men, and 
glucocorticosteroid-induced osteoporosis [15, 16–20]. 
Two rhPTH formulations are available on the market: 
one of them contains full rhPTH amino acid chain 1-84 
(Preotact 1, approved only in EU), while the other, 
contains only the N-terminal active PTH fragment 1–34 
(teriparatide — FORTEOTM, ForsteoTM). The biological 
activity of rhPTH is associated with N-terminal frag-
ment, which binds to PTH 1 receptor and mimics the 
activity of endogenous parathormone [21]. Full-length 
rhPTH 1-84 contains not only the N-terminal fragment, 
but also the C-terminal one, which binds to CPTHR 
receptor and displays different biological activity — it 
enhances the apoptosis of osteocytes [22]. Following 
subcutaneous injection, the rhPTH preparations are 
absorbed rapidly and the half-life is 1 hour for rhPTH 
1-34 and 2.5 hours for rhPTH 1-84, with bioavailability 
of 95% and 55%, respectively [23, 24]. It has been ob-
served that 4–6 hours after subcutaneous injection of 
teriparatide, a peak increase in serum calcium levels by 
approx. 0.4 mg/dL occurs, and that it persists for about 
6 hours and returns to baseline levels after 16–24 hours, 
which has been used in the treatment of hypocalcaemia 
[19, 25]. Initially, teriparatide makes bone formation 
markers increase and after some time, and bone resorp-
tion markers are elevated, which is related to intensive 
bone remodelling and the dominance of resorption 
process; therefore, long-term use of rhPTH products in 
osteoporosis is not indicated — the treatment should 
not exceed 18–24 months [7, 26].
This article is the first Polish presentation of possible 
teriparatide use in the treatment of severe hypocal-
caemia based on three different cases of postoperative 
hypoparathyroidism. 
Material and methods
Case no. 1 
A female patient (52) with postoperative hypoparathy-
roidism, following total thyroidectomy and the removal 
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of left lower parathyroid gland due to hyperparathy-
roidism (16 April 2013) was referred to the Department 
of Endocrinology, Metabolic Diseases, and Internal Dis-
eases at Pomeranian Medical University in Szczecin be-
cause of persistent symptoms of severe hypocalcaemia 
despite continuous, high-dose supplementation with 
calcium and vitamin D. The patient was also hospital-
ised twice at the internal diseases ward because tetany 
symptoms recurred as soon as intravenous calcium sub-
stitution treatment was discontinued, despite the use 
of oral calcium products — calcium carbonate 4 g/day, 
alphacalcidol 3 µg/day, magnesium hydroaspartate 
900 mg/day, and hydrochlorothiazide 25 mg/day. 
Based on the patient’s medical history, the diagnosis 
of left lower parathyroid adenoma took about two years. 
Because of increasing fatigue, weight loss, generalised 
osteoarticular pain, extensive atrophic paradontitis, 
nephrolithiasis with recurrent infections, and depres-
sion, the patient was admitted to different hospital 
departments — lung tumour and myeloma were ruled 
out, and the patient even received palliative radiation 
therapy on both scapulas, but bone metastases were 
eventually ruled out. Antidepressant treatment was also 
started. Further diagnostic tests demonstrated hyper-
calcaemia, and consequently the parathormone levels 
were determined (PTH, 1522.4 pg/mL) and MIBI-TC99m 
scintigraphy of parathyroid glands was performed. 
The findings included a focus of increased marker 
uptake visualised in the lower pole of left thyroid lobe, 
suggestive of left lower parathyroid adenoma (Fig. 1). 
Total thyroidectomy and the resection of left lower 
parathyroid gland were performed resulting in in-
traoperative decline of PTH levels from 1500 pg/mL 
to 85 pg/mL. After that, low PTH and calcium levels 
were observed as well as hyperphosphataemia, despite 
intensive use of calcium, magnesium, and vitamin D 
with recurrent severe symptoms of tetany.
On the day of admission to the Department, the 
patient complained of continuous tingling and numb-
ness as well as periodic muscle cramps in the limbs 
and face, generalised bone pain, dry skin, hair loss, nail 
brittleness, and depressed mood. 
Physical examination findings included the follow-
ing deviations: cachexia — BMI = 15.9 kg/m2, dry skin, 
thinning of hair, increased thoracic kyphosis, positive 
Chvostek sign and Trousseau’s sign, and advanced 
dental caries. 
Laboratory tests demonstrated hypocalcaemia, hy-
perphosphataemia, low PTH levels, low 24-hour elimi-
nation of calcium and phosphorus and elevated bone 
turnover parameter, and alkaline phosphatase (ALP) 
(Table I). Treatment was based on 11 g/day calcium 
carbonate, 3000 mg/day magnesium citrate, vitamin D 
(6 µg/day alphacalcidol and 0.075 mg/day cholecalciph-
erol) and 25 mg/day hydrochlorothiazide, and because 
of recurrent symptoms of tetany intravenous calcium 
infusions were given every two days (2 g calcium chlo-
ride). Attempts to switch to oral-only therapy resulted in 
the symptoms of hypocalcaemia with very low calcium 
and high phosphorus levels. Endoscopy of upper gas-
Figure 1. Pathological marker accumulation focus in parathyroid scintigraphy MIBI-TC99m in the lower pole of left thyroid lobe — left 
parathyroid adenoma
Rycina 1. Ognisko patologicznego gromadzenia znacznika w scyntygrafii przytarczyc MIBI-TC99m w dolnym biegunie lewego płata 
tarczycy — gruczolak lewej przytarczycy
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trointestinal tract was performed and the specimens of 
duodenum were sampled — malabsorption syndrome 
was excluded. DEXA densitometry revealed osteoporo-
sis BMD L1-L4 0.799 g/cm2, T-score — 3.4 (Fig. 2).
After 11 weeks of hospitalisation at the Department, 
the patient’s physical and mental condition improved, 
her body weight increased by 7 kg (BMI — 18.4 kg/m2), 
and the continuous sensation of tingling and numbness 
in the limbs and face subsided, but each attempt to 
discontinue IV calcium treatment resulted in the recur-
rence of tetany symptoms, irrespective of oral calcium 
and magnesium dosing. The patient also suffered from 
generalised bone pain, although it was less severe. As 
the treatment used so far proved ineffective and it was 
A. BMD of the spine in anterior-posterior projection; date: 09-May-2013
B. Bone mineral density of the spine in anterior-posterior projection; date: 26 March 2014
Figure 2. Bone mineral density before and after 10 months of treatment for severe symptomatic hypoparathyroidism following the 
removal of parathyroid adenoma; Lunar bone densitometer
Rycina 2. Wynik badania gęstości mineralnej kości przed i po 10 miesiącach leczenia z powodu ciężkiej, objawowej niedoczynności 
przytarczyc po usunięciu gruczolaka przytarczyc, wykonane aparatem Lunar
Densitometry: USA (Lunar)
Region BMD [g/cm3] T-score Z-score
L1 1.428 2.5 3.3
L2 1.447 2.1 2.9
L3 1.369 1.6 2.5
L4 1.305 0.9 1.7
L1–L4 1.387 1.7 2.5
Densitometry: USA (Lunar)
Region BMD [g/cm3] T-score Z-score
L1 0.805 –2.7 –1.6
L2 0.866 –2.8 –1.6
L3 0.761 –3.7 –2.5
L4 0.779 –3.5 –2.4
L1-L4 0.799 –3.2 –2.0
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impossible to discontinue intravenous therapy, the deci-
sion was made to start teriparatide (Forsteo; Eli Lilly) 
20 µg/0.08 mL in daily subcutaneous injections given 
for 28 days. Three days after the start of teriparatide 
therapy, clinical and laboratory features of normal cal-
cium levels prevailed (Table I) despite the fact that the 
ions were supplemented by oral route only — and the 
substitution doses of the drugs were reduced on the 
next days. The patient was discharged from hospital 
and her outpatient treatment during the next four 
weeks included the following drugs in addition to teri-
paratide: calcium carbonate 5 g/day with dose reduction 
to 3 g/day, alphacalcidol 2 µg/day and cholecalcipherol 
0.075 mg/day, magnesium citrate 3000 — 2000 mg/day, 
and hydrochlorothiazide 25 mg. While the patient was 
on this treatment, tetany symptoms were not observed, 
and calcium, magnesium, and phosphate levels re-
mained within normal ranges. At follow-up visit one 
week after last teriparatide dose, the patient reported 
that the symptoms recurred — she had tingling and 
periodic cramps in the limbs, although less severe, and 
laboratory tests demonstrated slightly reduced calcium 
levels, hyperphosphataemia, low parathormone level, 
normal 24-hour calcium elimination with reduced phos-
phate elimination, and normal vitamin D levels (Table I). 
Oral doses were increased and the following drugs 
were used on an outpatient basis: calcium carbonate 
6 g/day, alphacalcidol 2 µg/day, and cholecalcipherol 
0.075 mg/day, while magnesium citrate 3000 mg/day 
and hydrochlorothiazide 25 mg were continued as be-
fore. Gradual relief and resolution of clinical symptoms 
were observed during the next few weeks, and two 
months later laboratory normocalcaemia was achieved, 
while the patient had oral-only ion substitution therapy. 
At the next visit five months later, laboratory findings 
included hypercalcaemia, low PTH levels, slightly el-
evated 24-hour calcium elimination, normal phosphate 
elimination, and normal ALP levels (Table I). The patient 
reported having no tetany symptoms for five months, 
no bone pain for three months and she did not take 
calcium preparation (it was discontinued eight months 
after surgery), and she continued treatment with vita-
min D preparation (alphacalcidol and cholecalcipherol). 
Physical examination showed normal BMI (20.9 kg/m2) 
and the patient’s mental status was normal. Follow-up 
densitometry of the spine demonstrated high bone min-
eral density BMD L1-L4 = 1.387 g/cm2, T-score + 1.37, 
T-score increased by 73% after 10 months (Fig. 2). At the 
time of writing, the patient requires treatment with low 
substitution doses of vitamin D3 and calcium (500 mg 
calcium carbonate per day and 1 ug alphacalcidol) 
despite persistent very low PTH levels. 
Case no. 2
A female patient (33) with iatrogenic hypoparathy-
roidism, after total thyroidectomy in 1996 due to thyroid 
papillary carcinoma, with congenital tubulopathy as-
sociated with renal calcium and magnesium loss was re-
ferred to the Department of Endocrinology at the Medi-
cal University of Warsaw because of recurrent, severe, 
life-threatening tetany attacks. Uncontrolled, very pain-
ful muscle cramps with lockjaw and periodic breathless-
Table I. Calcium-phosphate balance parameters in subsequent months of hospitalisation in a patient with symptomatic 
hypoparathyroidism after resection of parathyroid adenoma and teriparatide treatment
Tabela I. Stężenia parametrów gospodarki wapniowo-fosforanowej w trakcie kolejnych miesięcy hospitalizacji pacjentki 
z objawową niedoczynnością przytarczyc po usunięciu gruczolaka przytarczyc i po zastosowaniu teryparatydu
Parameter/normal ranges Baseline V–VII 2013 VIII 2013 VIII 2013 — 3 VIII 2013 — 8 IX 2013 III 2014
Total Ca (2.1–2.54 mmol/L) 1.16 1.34–1.89 1.9 2.38 2.36 2.05 2.64
Ionised Ca  
(1.12–1.32 mmol/L)
0.6 0.56–1.08 0.92 1.23 1.26 1.02 1.3
P (0.81–1.45 mmol/L) 1.5 2.1–1.4 1.8 1.5 1.4 1.6 1.1
Vit. OHD (30– 80 ng/mL) 23 12.5–37.5 28.9 na na 48.4 29.5
PTH (11–67 pg/mL) 4.3 5.8–9.44 3.36 na na < 3  < 3
Mg (0.66–1.07 mmol/L) 0.8 0.7–0.97 0.76 0.72 0.63 0.66 0.66
Ca in 24h urine collection 
(0.0–6.2 mmol/d)
0.86 1.62–2.04 6.98 6.24 2.71 3.59 6.3
P in 24h urine collection 
(12.9–42 mmol/d)
0.21 0.6–0.21 15.75 20.6 15.5 1.71 15.4
ALP (35–105 U/L) 304 268 112 na 105 na 77
Total Ca — total calcium; Ionized Ca — ionized calcium; P — phosphates; Vit. OHD — 25 hydroxyvitamin D; PTH — parathormone; Mg — magnesium; Ca in 24h 
urine collection — 24-hour calcium elimination; P in 24h urine collection — 24-hour phosphate elimination; ALP — alkaline phosphatase; VIII 2013 -3 — after starting 
teriparatide treatment on day 3; VIII 2013 -8 — after starting teriparatide treatment on day 8; na — not assayed
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ness were observed on the first days following thyroid-
ectomy. Despite treatment with high doses of active 
vitamin D (alphacalcidol up to 10 µg), calcium carbonate 
(up to 12g/day), and hydrochlorothiazide 25 mg/day, 
the attacks recurred every 2–3 days and required in-
travenous calcium infusion at Hospital Emergency De-
partments. As a consequence, the patient’s peripheral 
veins were damaged, narrowed, and obstructed, and 
eventually a venous port was inserted into the vein. 
Four attempts were made to transplant the homogenate 
of parathyroid cells, but all of them were unsuccessful. 
In 2008, the port placed in the right subclavian vein 
was infected and damaged permanently. Since then, 
every effort was made to maintain the port placed in 
left subclavian vein. Currently, after another admission 
to the Department, infection of the venous port — the 
only venous access — has been observed, which made 
intravenous therapy impossible. Laboratory findings 
included hypocalcaemia, hyperphosphataemia, and 
low PTH levels (Table II). Because of the life-threatening 
condition of the patient, teriparatide bridging therapy 
was prepared (Forsteo; Eli Lilly) with subcutaneous 
injections of 20 µg/0.08 mL dose started immediately 
after admission to the Department. There was a com-
plete resolution of clinical symptoms of hypocalcae-
mia, but teriparatide dose was administered every 
8–12 hours. Normocalcaemia was obtained on day 16 
of teriparatide treatment (Table II), which triggered 
a once daily dose reduction. The dose reduction did not 
result in the onset of clinical symptoms of hypocalcae-
mia. Hypercalciuria persisted as a result of congenital 
renal defect. Treatment with rhPTH made it possible 
to restore the venous port. At the same time, during 
teriparatide treatment, the patient has not suffered from 
any tetany symptoms for the first time since 1996. Once 
the infection was cured, rhPTH was discontinued and 
substitution treatment with oral calcium, magnesium, 
and vitamin D preparations was administered as before. 
Unfortunately, tetany attacks recurred. Currently, the 
patient is being treated with vitamin D (alphacalcidol 
10 mg) and calcium carbonate (up to 9 g/day), and she 
requires calcium infusions every 2–3 days because of 
tetany symptoms. 
Case no. 3
Female patient (52) with a history of laryngo-phar-
yngo-oesophagectomy with lymphadenectomy due 
to relapsed cancer of laryngopharynx and cervical 
oesophagus, after strumectomy, after alimentary tract 
reconstruction with free autograft of small intestine 
(20 August 2012) complicated with enterocutaneous fis-
tula, fed through percutaneous endoscopic gastrostomy 
(PEG), and treated with clonazepam for epilepsy, was 
referred to the Department of Internal Diseases and 
Endocrinology at the Medical University of Warsaw in 
December 2012 because of severe symptomatic postop-
erative hypoparathyroidism, resistant to calcium and 
vitamin D3 treatment. 
On the day of admission to the Department, the 
patient complained about recurrent, paroxysmal muscle 
cramps in the face and limbs, and severe abdominal 
pain. Laboratory tests revealed hypocalcaemia, hyper-
phosphataemia, and low PTH levels (Table III). Despite 
intensification of PEG-administered drugs: 16 g/day cal-
Table II. Calcium-phosphate balance parameters on subsequent days of teriparatide treatment in a patient with symptomatic 
hypoparathyroidism, after thyroidectomy because of papillary thyroid cancer, with infection of vascular port
Tabela II. Stężenia parametrów gospodarki wapniowo-fosforanowej w trakcie kolejnych dni stosowania teryparatydu 
u pacjentki z objawową niedoczynnością przytarczyc, po tyreoidektomii z powodu raka brodawkowatego tarczycy, z zakażeniem 
portu naczyniowego
Parameter/normal ranges Baseline V–VII 2013 VIII 2013 VIII 2013 — 3 VIII 2013 — 8 IX 2013 III 2014
Total Ca (2.1–2.54 mmol/L) 1,53 1.51 1.58 1.72 1.71 2.4 2.3
Ionized Ca (1.12–1.32 
mol/L)
0,8 0.76 0.77 0.83 0.83 1.21 1.13
P (0.81–1.45 mmol/L) 1,84 1.85 0.87 1.03 1.07 1.00 1.28
Vit. OHD (30– 80 ng/mL) 27.96 na na 24.18 na 19.96 na
PTH (11–67 pg/mL) 1.32 na na na na na na
Mg (0.66–1.07 mmol/L) 0.63 0.71 0.71 0.75 0.71 0.76 0.72
Ca in 24h urine collection
(0.0–6.2 mmol/d)
5.03 na 10.4 na na 9.2 12.9
ALP ( 35–105 U/L) 69 131 na na na 115 na
Total Ca — total calcium; Ionized Ca — ionised calcium; P — phosphates; Vit. OHD — 25 hydroxyvitamin D; PTH — parathormone; Mg — magnesium; Ca in 24-hour 
urine collection — 24-hour calcium elimination; ALP — alkaline phosphatase; na — not assayed
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cium carbonate, 4 µg/day alphacalcidol, and 2000 mg/day 
magnesium hydroaspartate, tetany cramps recurred 
every 1–2 days and laboratory features of hypopar-
athyroidism persisted. During hospitalisation, the 
patient experienced a hypocalcaemic crisis. Intravenous 
calcium and magnesium formulations were started, 
resulting in the relief of symptoms, but these failed 
to bring the expected effects. A decision was made 
to start teriparatide treatment (Forsteo; Eli Lilly) at 
20 µg/0.08 mL administered twice daily as subcutaneous 
injections. After the first teriparatide dose, the patient 
had nausea and vomiting, but these occurred once 
and no further adverse reactions were observed as the 
treatment continued. After starting teriparatide therapy, 
the patient did not present any clinical signs of hypoc-
alcaemia, and the parameters of calcium-phosphate 
balance gradually returned to normal (Table III). Six 
weeks after the beginning of teriparatide therapy, its 
dose was reduced to 2 × 20 µg every second day. Treat-
ment lasting two months resulted in the correction of 
laboratory parameters of calcium-phosphate balance 
(Table III). On the following weeks, the patient did not 
report any open tetany symptoms or its equivalents.
Discussion
The three cases presented in our article have one com-
mon feature: the presence of severe, life-threatening 
hypocalcaemia resistant to standard treatment. Each 
of them, however, presents a different clinical problem 
underlying the postoperative hypoparathyroidism. 
In case no. 1, the underlying cause of the surgery is 
hyperparathyroidism associated with adenoma of the 
lower left parathyroid gland. In case no. 2, the damage 
of parathyroid glands was the consequence of total 
thyroidectomy due to papillary thyroid cancer. In case 
no. 3, parathyroid glands were removed during major 
oncology surgery because of cancer of the lower phar-
ynx and cervical oesophagus.
Hypocalcaemia following the surgery of parathyroid 
adenoma is a relatively frequent phenomenon and may 
be of temporary nature (transient suppression of func-
tion and impaired blood supply to other parathyroid 
glands and hungry bone syndrome) — or it may be per-
manent as a result of intraoperative damage or resection 
of all parathyroid glands [3, 27, 28]. Treatment effects are 
usually obtained with standard doses of oral calcium 
and vitamin D preparations, sometimes combined with 
a thiazide diuretic [4]. However, in rare cases, prolonged 
symptomatic hypocalcaemia is observed despite oral 
and intravenous therapies. 
In patient no. 1, who was operated for parathyroid 
adenoma, even long-term supplementation with high 
doses of calcium carbonate at 11 g/day and alphacalcidol 
at 6 µg/day proved ineffective and required constant 
intravenous infusions of calcium ions. The patient was 
also treated with thiazide diuretics in order to enhance 
renal calcium reabsorption [4, 29] and received supple-
mentation of magnesium ions because their deficiency 
is a well-known cause of hypocalcaemia [30], but this 
also proved ineffective. Based on endoscopy with the 
sampling of duodenal specimens and the determina-
tion of anti-transglutaminase antibodies, malabsorption 
syndrome was ruled out as a potential cause of impaired 
calcium absorption in the digestive tract. A frequent 
complication following surgical treatment of primary 
hyperparathyroidism is hungry bone syndrome (HBS), 
especially in patients with advanced bone changes asso-
ciated with this disease [31]. Our patient suffered from 
generalised bone pain, low mineral density of lumbar 
spine (BMD L1-L4 T-score — 3.4), and elevated serum 
levels of alkaline phosphatase (ALP), which could 
indicate enhanced bone remodelling with intensive 
re-calcification of bone tissue. Hungry bone syndrome 
is observed in 13–30% of cases following parathyroid 
surgery [32]; in patients with bone changes caused by 
hyperparathyroidism the incidence of HBS is increased 
to 25–90%, while the absence of bone changes is as-
Table III. Calcium-phosphate balance parameters on subsequent days of teriparatide treatment in a patient with symptomatic 
hypoparathyroidism, after resection of laryngopharynx and cervical oesophagus due to cancer
Tabela III. Stężenia parametrów gospodarki wapniowo-fosforanowej w trakcie kolejnych dni stosowania teryparatydu 
u pacjentki z objawową niedoczynnością przytarczyc po resekcji gardła dolnego i szyjnej części przełyku z powodu raka
Parameter/normal ranges Baseline 06.02.12 08.02.12 27.12.12 30.12.12 19.01.13 07.02.13
Total Ca (2.15–2.60 mmol/L) 1.23 1.30 1.96 1.86 2,03 1,96 2.20
Ionized Ca (1.15–1.29 mol/L) 0.65 0.73 1,03 1,00 1.12 0.97 1.12
P (0.81–1.45mmol/) 2.19 2,04 1.24 1.64 1.36 1.89 1.11
PTH (11–67 pg/mL) 2.8 na na 4,15 na na na
Mg (0.66–1.07 mmol/L) na na na 0,60 na 0.66 0.70
Total Ca — total calcium; Ionised Ca — ionised calcium; P — phosphates; PTH — parathormone; Mg — magnesium; na — not assayed
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sociated with a risk reduction to 0–6% [28]. Most HBS 
definitions include the presence of hypocalcaemia in 
a patient subjected to surgery for hyperparathyroidism, 
as well as hypophosphatemia and hypomagnesaemia 
as an effect of bone remineralisation [28, 33]. Some au-
thors define HBS-related hypocalcaemia as the values 
< 8.5 mg/dL and hypophosphatemia as the values 
< 3.0 mg/dL [27] with hypocalcaemia persisting for over 
four days despite calcium ion supplementation, with 
normal vitamin D levels in serum [31]. Parathormone 
serum levels are normal or elevated [27, 28, 34]. It is 
believed that severe hypocalcaemia observed in HBS is 
a consequence of increased calcium ion inflow to bones 
as a result of rapid compensation for earlier effects of 
high PTH levels on the resorption of osteoclasts, leading 
to decreased activation rate of new sites of bone remod-
elling, inhibition of resorption, and continued bone for-
mation [28]. It is commonly believed that the factors pre-
disposing for HBS include old age, the size of removed 
parathyroid glands, high preoperative calcium, ALP 
and PTH levels, changes in bone system (bone cysts, 
brown tumours, subperiosteal bone resorption, osteo-
paenia, osteoporosis), vitamin D deficiency [27, 28, 35], 
or parathyroid cancer [36]. On the other hand, Latus 
et al. [31], having analysed 84 patients after surgery for 
secondary hyperparathyroidism, found that the risk of 
HBS is higher in younger patients and in patients with 
low preoperative calcium levels. These authors also 
observed that preoperative vitamin D therapy did not 
prevent HBS and had no impact on the duration of post-
operative intravenous calcium supplementation [31]. 
Literature reports consistently claim that preoperative 
bisphosphonate treatment may prevent hungry bone 
syndrome after parathyroidectomy, both in primary 
and secondary hyperparathyroidism, although in the 
long perspective, this treatment may potentially delay 
bone remodelling [37–39]. HBS treatment is long-lasting 
and usually requires high doses of calcium and vitamin 
D preparations [33, 35]. Prolonged hypocalcaemia 
despite treatment is the reasons for long hospitalisa-
tions. Araya et al. [40] reported that mean duration of 
hospital treatment was 19 days. On the other hand, 
Juarez-Leon et al. [33] described a female patient with 
HBS, who required oral and intravenous supplementa-
tion of calcium for up to three months. Our patient no. 
1 presented high preoperative PTH and calcium levels 
and severe osteoporosis with persistent postoperative 
hypocalcaemia but also with hyperphosphataemia, and 
low vitamin D and PTH levels, which corresponds to 
the diagnosis of postoperative hypoparathyroidism 
with coexistent hungry bone syndrome being respon-
sible for the symptoms reported by the patients [34]. 
In our patients no. 2 and 3, severe hypocalcae-
mia was not only the consequence of postoperative 
hypoparathyroidism but also a result of underlying 
disease making the hypocalcaemia even more severe. 
In patient no. 2 this underlying disease was congenital 
tubulopathy associated with renal loss of calcium and 
magnesium, while in case no. 3, calcium absorption 
might have been impaired as a result of alimentary 
tract reconstruction. Literature data indicate that se-
vere hypocalcaemia may develop as a consequence 
of enhanced renal loss of calcium in patients after 
kidney transplantation with coexistent postoperative 
hypoparathyroidism [8] as well as in patients with post-
operative hypoparathyroidism undergoing Roux-en-Y 
gastric bypass (RYGB) bariatric surgery with subsequent 
impairment of calcium gastrointestinal absorption [7].
Like other authors [5, 9], we also observed severe 
postoperative hypoparathyroidism in our patients, 
which was resistant to treatment and which coexisted 
with low PTH levels, requiring many weeks of intrave-
nous ion substitution. Although necessary, in the long 
run this treatment may trigger symptoms associated 
with hypercalciuria and ectopic calcification of soft 
tissues [4, 41]. Attempts have been made for several 
years to treat such cases with recombinant human PTH 
(rhPTH) using the full length PTH molecule (1-84), as 
well as with active short PTH (1-34) [7–9, 11, 42–47]. 
Daily subcutaneous injections of rhPTH (1-34) resulted 
in rapid resolution of clinical features of hypocalcaemia 
in all our patients, while laboratory features of normoc-
alcaemia was achieved on day 3 in patient no. 1, on 
day 16 in patient no. 2, and after 2 months in patient 
no. 3 (Tables I–III). Like other authors [8, 9, 43, 45, 48], 
we also demonstrated the efficacy of teriparatide in 
reducing urine elimination of calcium. Rapid effect of 
normocalcaemia, observed after one or more days of 
subcutaneous rhPTH added to standard treatment with 
calcium and vitamin D preparations, has been also em-
phasised by other authors [11, 47]. On the other hand, 
Puig-Domingo et al. [9] described a female patient who 
failed to obtain normocalcaemia with subcutaneous in-
jections of teriparatide as frequently as 4–6 times a day 
— it was only after using a teriparatide infusion pump 
that the parameters of calcium-phosphate balance were 
effectively corrected and the symptoms subsided; the 
treatment lasted one year. Because of the high cost of 
teriparatide treatment, we used a short-term therapy 
lasting 4 to 12 weeks, which proved sufficient to control 
serum calcium levels with oral calcium and vitamin D 
formulations in patients no. 1 and 3, and additionally in 
patient no. 1 the symptoms of hypocalcaemia subsided 
completely during the next few days. We also observed 
reduced use of calcium and vitamin D preparations in 
the following months, which was described in earlier 
reports [11, 45, 49]. During the four-year rhPTH (1-84) 
therapy in patients with hypoparathyroidism, Cusano 
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et al. [45] observed decreased use of calcium supple-
mentation by 37%, vitamin D use decline by 45%, while 
26% of analysed patients did not require further vitamin 
D treatment. In all cases of rhPTH (1-34) use in severe 
postoperative hypocalcaemia after renal transplantation 
and previous parathyroidectomy, Nogueira et al. [11] 
obtained normal calcium levels and decreased need for 
vitamin D and calcium doses, and after several months of 
treatment (treatment duration ranging from 1 month to 
32 months), teriparatide was no longer required. Among 
the three patients described in our report, only patient 
no. 2 experienced the recurrence of severe hypocalcae-
mia following the discontinuation of teriparatide, which 
may be related to short duration of treatment and the 
presence of congenital tubulopathy with considerable 
loss of calcium and magnesium ions with urine.
Another effect of rh PTH (1-34) and rhPTH (1-84) 
treatment is the improvement of bone remodelling 
dynamics and the restoration of normal bone metabo-
lism [50]. The anabolic effect of teriparatide on bone 
tissue is the consequence of restoring pulses of PTH 
secretion and increased osteoblast activity with the 
predominance of bone formation process, which has 
been used so far in the treatment of osteoporosis [51]. 
The considerable 73% increase in bone mineral density 
(BMD) of lumbar spine obtained in our patient no. 1 was 
many times higher than the BMD increase observed by 
Puig-Domingo et al. after one-year teriparatide treat-
ment (7%) [9] or BMD reported by Cusano after four-
year follow-up (5.5 ± 9%) [45]. Contrary to our findings, 
Sikjaer et al. [49] demonstrated a slight but significant 
decrease in lumbar vertebral BMD (-1.76 ± 1.0%) with 
rh PTH (1-84) treatment, but these results are difficult 
to compare as the study lasted for six months. However, 
this high BMD increase observed in our patient was 
similar to that reported by other authors in patients 
with hungry bone syndrome (27–65%) [28] and was 
probably the result of initial low bone mass and very 
intense recalcification of bone tissue after treatment. 
The potential coexistence of hypoparathyroidism and 
hungry bone syndrome as complications of parathy-
roidectomy requires further studies. 
The safety of recombinant human parathormone 
(rhPTH) is highlighted in available literature, and, just 
like other authors [9, 11, 47], we did not observe any 
significant adverse reactions — the same observation 
was also confirmed by Cusano [45] in the follow-up of 
longest duration published so far for rhPTH. There is 
also a hypothesis that a correlation exists between the 
quality of life deterioration and the absence of para-
thyroid hormone, which is attributed to the beneficial 
effect of parathormone on the central nervous system 
[52]. A positive effect on quality of life is another aspect 
reported during rhPTH treatment for hypoparathy-
roidism [50, 52]. Until recently, hypoparathyroidism — 
i.e. PTH deficiency — was the only hormone deficiency 
disease without approved substitution therapy. Since 
2015, full-length recombinant human parathormone 
[rhPTH (1-84); Natpara] has been approved in the 
USA as an adjunct to calcium and vitamin D to control 
hypocalcaemia in patients with hypoparathyroidism 
[53]. The onset and duration of treatment has not been 
specified and the most dangerous potential complica-
tion observed in rat studies is osteosarcoma of bones 
[54]. In Europe, rhPTH has not been approved yet for 
the treatment of severe hypocalcaemia associated with 
postoperative hypoparathyroidism. 
Subcutaneous daily injections of rhPTH (1-84) and 
rhPTH (1-34) seem a very promising therapeutic option 
in postoperative hypoparathyroidism, not only for the 
control of hypocalcaemia, but also in relation to other 
aspects of the disease such as skeletal dysfunction and 
quality of life deterioration [50, 52]. Our studies also 
support the justified use, efficacy, and safety of such 
treatment. It should be pointed out that short teri-
paratide treatment prescribed by our team in severe 
hypocalcaemia associated with postoperative hypopar-
athyroidism, in 2 out of 3 presented patients, proved 
sufficient for further control of calcium levels with 
oral calcium and vitamin D products and for complete 
correction of calcium levels in the next months in one 
patient. This argument is of particular interest when 
discussing the expected costs of rh PTH treatment.
Conclusions
The use of recombinant human teriparatide results in 
the control of severe hypocalcaemia requiring intrave-
nous calcium infusions in patients with postoperative 
hypoparathyroidism.
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